Quantcast
Home > Quotes > CUE
CUE

Cue Biopharma, Inc. Common Stock (CUE) Quote & Summary Data

$5.13
*  
0.05
0.98%
Get CUE Alerts
*Delayed - data as of Dec. 13, 2018  -  Find a broker to begin trading CUE now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
14.5
Today's High / Low
$ 5.2556 / $ 4.98
Share Volume
58,720
50 Day Avg. Daily Volume
98,867
Previous Close
$ 5.08
52 Week High / Low
$ 17.99 / $ 4.47
Market Cap
103,283,655
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.44

Intraday Chart

Shares Traded

Share Volume:
58,720
50 Day Avg. Daily Volume:
98,867

Trading Range

The current last sale of $5.13 is 14.77% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 5.2556 $ 17.99
 Low: $ 4.98 $ 4.47

Company Description (as filed with the SEC)

We are an innovative biopharmaceutical company developing a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. We believe our innovative CUE Biologics(TM) platform approach to selectively modulate disease relevant T cells, provides a transformative solution to the challenges facing prevailing immunotherapeutics. By directly engaging and modulating disease relevant T cells in the patient's body via an injectable drug, we believe our biologic drug candidates will be able to realize the true potential of immune modulation. Through our proprietary CUE Biologics(TM) platform, we believe we are uniquely positioned to become a prominent and leading player in immunotherapy, immuno-oncology, and autoimmune disease.  ... More ...  


Risk Grade

Where does CUE fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 5.14
Open Date:
Dec. 13, 2018
Close Price:
$ 5.13
Close Date:
Dec. 13, 2018

Consensus Recommendation

Analyst Info